Business Wire - February 27, 2003

Planned Parenthood Golden Gate, an affiliate of the Planned Parenthood Federation of America, serves more than 65,000 men, women and teens in the San Francisco Bay area each year. Its nine health centers, located in Alameda, Marin, San Francisco, San Mateo and Sonoma counties, perform approximately 5,100 HIV tests per year.

"We decided to provide urine HIV testing to increase the convenience for our clients, and potentially increase HIV testing in the Bay Area," said Dian Harrison, President and CEO of Planned Parenthood Golden Gate. "The ability to screen for HIV, pregnancy and sexually transmitted diseases from the same urine specimen provides added convenience for both our clients and our healthcare providers. We also anticipate cost savings from reducing the need for multiple client samples."

"The strong partnership between Calypte and Planned Parenthood Golden Gate represents another milestone for Calypte in raising awareness for urine-based testing, as well as increasing distribution through proactive healthcare providers," said Nancy Katz, Calypte's President and CEO. "As one of the larger Planned Parenthood affiliates, this relationship represents an excellent opportunity to demonstrate the benefits of urine testing to other Planned Parenthood affiliates. Based on our experiences with other organizations, we expect Planned Parenthood Golden Gate will experience an increase in voluntary testing for HIV because the test is completely non-invasive and simple to collect."

Calypte will also hold a conference call today at 11:00 a.m. (ET), 8:00 a.m. (PT) to discuss its fourth quarter and year-end earnings results. Investors can access the call from the investor section of the Calypte web site, www.calypte.com. Investors in the U.S. and Canada interested in participating in the conference call may dial 877/282-0743 and reference the Calypte Biomedical call. International investors may dial 703/871-3073. Calypte recommends dialing into the call approximately 10 minutes prior to the scheduled start time. The webcast will be available until March 27, 2003. A telephone replay will be available through March 1, 2003 by calling 888/266-2081. International callers should dial 703/925-2533 for the replay. The replay confirmation code is 6411592.

About Planned Parenthood Golden Gate:

Planned Parenthood Golden Gate is a non-profit health organization that has been helping women, men and teens make responsible choices for more than 70 years. Since 1929, Planned Parenthood Golden Gate has been committed to delivering the highest quality reproductive health care, teaching responsible and age-appropriate sexuality education and has been working diligently to protect a woman's right to choose. They are the second largest affiliate of the Planned Parenthood Federation of America. Planned Parenthood Golden Gate president and CEO Dian Harrison has also been appointed to Calypte's Board of Directors, effective February 24, 2003.

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K/A(No.3) for the year ended December 31, 2001 and its subsequent filings with the SEC.

CONTACT: Calypte Biomedical Corporation Pamela South, 510/749-5100, psouth@calypte.com or Lippert/Heilshorn & Associates (Investor Relations) Brendan Lahiff or Kirsten Chapman, 415/433-3777, brendan@lhai-sf.com

SOURCE: Calypte Biomedical Corporation

030227
BW030218

Copyright © 2003 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .